Real-world five-year outcomes of FlexyRap cobalt-chromium rapamycin-eluting stents with biodegradable polymer in patients with coronary artery disease.

Background: The use of biodegradable polymer drug-eluting stents (BP-DES) has been proven to minimize restenosis and stent thrombosis. The current post-marketing monitoring was observed at the 5-year clinical outcomes of individuals who had been treated with FlexyRap DES in the real world.

Aim: To assess the safety and effectiveness of FlexyRap DES at the 5-year follow-up in real-world settings.

Reconstructing the Intrinsic Statistical Properties of Intermittent Locomotion Through Corrections for Boundary Effects.

Locomotion characteristics are often recorded within bounded spaces, a constraint which introduces geometry-specific biases and potentially complicates the inference of behavioural features from empirical observations. We describe how statistical properties of an uncorrelated random walk, namely the steady-state stopping location probability density and the empirical step probability density, are affected by enclosure in a bounded space. The random walk here is considered as a null model for an organism moving intermittently in such a space, that is, the points represent stopping locations and the step is the displacement between them.

First in man study of a new semi-open cell design Zephyr cobalt-chromium stent in large vessels and conduits.

Objectives: We present a first-in-man clinical use of a new hybrid design stent in stenosed large vessels. Its unique C and S polylinks prevent foreshortening without compromising its strength. Its thin profile permits use of smaller introducer sheaths.

One-year outcomes of a NeoHexa sirolimus-eluting coronary stent system with a biodegradable polymer in all-comers coronary artery disease patients: Results from NeoRegistry in India.

Background: Biodegradable polymer drug-eluting stents (BP-DES) have shown to reduce restenosis rates and have low rates of stent thrombosis. The present postmarketing surveillance assessed 1-year clinical outcomes of patients who had received NeoHexa DES in real practice.

Aim: To investigate 1-year clinical outcomes of Neohexa DES in real practice.

Novel growth stent for the permanent treatment of vessel stenosis in growing children: an experimental study.

Stent implantation in stenotic vessels of infants and small children is problematic because there is no ideal stent model that is small enough to be easily introduced into the infant femoral vein or artery and, at the same time, large enough to be dilated during growth to adult vessel diameters. To overcome this problem, we designed a new stent, the growth stent. This growth stent is a balloon-expandable metal stent.

Duct-Occlud for Occlusion of Patent Ductus Arteriosus.

The Duct-Occlud Occlusion System (ATG Co., Malta, Europe) is the only coil-type device that has been specifically designed to close the patent ductus arteriosus (PDA). The Duct-Occlud coil has no Dacron feathers.